ATS 2020 Advance Program

12:10 LUNCH 1:00 Abdominal Vascular Bed Physiology M. Hoenig, MD, Boston, MA 1:50 Ultrasound Cases C. Baston, MD, MSCE, Philadelphia, PA 2:50 Break 3:00 Physiology of ECMO M.E. Prekker, MD, MPH, Minneapolis, MN CLINICAL • TRANSLATIONAL POSTGRADUATE COURSE PG28 STATE OF THE ART: LUNG CANCER IN 2020 Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited. Member: $350 In-Training Member: $200 Non-Member: $425 In-Training Non-Member: $300 Assemblies on Thoracic Oncology; Clinical Problems 8:00 a.m. - 4:00 p.m. Target Audience All providers caring for patients with lung nodules/lung cancer(pulmonologists, thoracic surgeons, radiation oncologists, NP/PAs).Those interested in the translational research being done in this field. Objectives At the conclusion of this session, the participant will be able to: • improve the use of CT screening in your practice setting/community; • integrate new treatment options for patients with stage III lung cancer; • gain new findings about the toxicities of immunotherapy. This course will provide a comprehensive review of topics in the evaluation and management of patients with lung cancer. We will start with an outstanding international example of tobacco control, discuss guidelines and practical tips for lung cancer screening, the new staging system and use of biomarkers for lung cancer detection and disease progression. The treatment of early stage, locally advanced and metastatic disease will be addressed, highlighting novel/minimally invasive approaches as well as the use, and toxicities of immunotherapy. Advancements in the evaluation and treatment of carcinoid and atypical carcinoid will also be highlighted. Interactive tumor boards will be held to highlight main teaching points and facilitate audience engagement Chairing: D.J. Feller-Kopman, MD, Baltimore, MD M.P. Rivera, MD, ATSF, Chapel Hill, NC 8:00 Introduction D.J. Feller-Kopman, MD, Baltimore, MD 8:05 BIG Tobacco and Electronic Nicotine Delivery Systems: Preventing Another Epidemic P. Galiatsatos, DrMed, Baltimore, MD 8:30 Lung Cancer Screening: The Data and the Disconnect R.S. Wiener, MD, MPH, Boston, MA 8:55 Liquid Biopsy: Ready for Prime Time? T. Evans, MD, Wynnewood, PA 9:20 Interactive Tumor Board D.J. Feller-Kopman, MD, Baltimore, MD 9:45 Break 10:00 Lung Cancer Staging: Past, Present, and Future A.V. Gonzalez, MD, MSc, Montreal, Canada 10:25 Pro/Con: Surgery Remains the Best Option for Early Stage Disease K. Yasufuku, MD, Toronto, Canada 10:50 Pro/Con: SBRT Is the Best Option for Early Stage Disease S. Feigenberg, MD, Philadelphia, PA 11:15 Interactive Tumor Board M.P. Rivera, MD, ATSF, Chapel Hill, NC 11:45 LUNCH 12:30 The Heterogeneity of Stage III Disease F. Detterbeck, MD, New Haven, CT ATS 2020 • Philadelphia, PA SATURDAY • MAY 16 33